While most myopes will have normal visual acuity with appropriate optical correction, myopia has significant public health consequences from a variety of perspectives, including financial, psychological, quality of life, and ocular co-morbidities.
Previous publications on bifocal and progressive spectacles have shown small degrees of myopia control. However, these effects appear only in children with certain ocular characteristics such as history of higher myopia progression rate, higher lags of accommodation and/or near phoria status.
There is evidence that myopia progression can be controlled optically, specifically with lenses that have been designed to impose myopic defocus on the periphery.
The following article is intended to provide clinicians with the basics for prescribing soft CL-based myopia management, so clinicians can begin prescribing this potentially beneficial treatment.
The use of the spectacle lenses for myopia management dates back to more than 30 years ago, when bifocal spectacle lenses prescribed to children with near-esophoria showed a reduction in myopia progression.
This network analysis indicates that a range of interventions can significantly reduce myopia progression when compared with single vision spectacle lenses or placebo.
It is crucial to prevent the onset of myopia and if not, to intervene at the earliest possible age to reduce the risk of progression.
The aim of this study was to investigate the effect of overnight orthokeratology (OOK) on ocular surface and meibomian gland dysfunction in teenagers with myopia.
A recent meta-analysis shows a beneficial effect of increased outdoor time with a reduction of risk for myopia development, but surprisingly not for progression.
The three most-researched treatment approaches that have validated a reduction in the long-term progression of myopia are orthokeratology, soft distance centered bifocal contact lenses, and antimuscarinic agents (atropine).